Please wait while we load the requested 10-K report or click the link below:
SAN DIEGO June 9, 2015 OncoSec Medical Inc. (OncoSec) (NASDAQ: ONCS), a company developing DNA-based intratumoral cancer immunotherapies, today announced financial results for the nine months ended April 30, 2015.
For the nine months ended April 30, 2015, OncoSec reported a net loss of $14.7 million, or $1.19 per share, compared to a net loss of $8.5 million, or $0.96 per share, for the same period last year. There were no revenues for the nine months ended April 30, 2015 or April 30, 2014.
Research and development expenses were $9.3 million for the nine months ended April 30, 2015, compared to $3.9 million for the nine months ended April 30, 2014. This increase in research and development expenses was primarily a result of increased salary related expenses, outside services costs, and lab supplies as the company further expands its internal research capabilities, research on next-generation electroporation devices, novel electroporation technologies, and combination studies, and increased costs associated with its clinical trials.
General and administrative expenses were $5.4 million for the nine months ended April 30, 2015, compared to $4.5 million for the nine months ended April 30, 2014. This increase in general and administrative expenses was primarily a result of increased salary related expenses due to increased headcount to support the growth in operations and increased conference fees and related travel, offset by a savings in professional services fees.
At April 30, 2015, OncoSec had $25.4 million in cash and cash equivalents, as compared to $37.9 million of cash and cash equivalents at July 31, 2014. OncoSec expects these funds will be sufficient to allow the company to continue to operate its business for at least the next 12 months.
· On May 18, 2015, OncoSec effected a reverse stock split, wherein each 20 shares of issued and outstanding common stock, were combined into and became one share of common stock, rounded up to the next whole share. No fractional shares were issued.
· On May 29, 2015, the companys common stock began trading on the NASDAQ Stock Market LLCs NASDAQ Capital Market tier, under the symbol ONCS.
The following information was filed by Oncosec Medical Inc (ONCS) on Tuesday, June 9, 2015 as an 8K 2.02 statement, which is an earnings press release pertaining to results of operations and financial condition. It may be helpful to assess the quality of management by comparing the information in the press release to the information in the accompanying 10-K Annual Report statement of earnings and operation as management may choose to highlight particular information in the press release.
View differences made from one year to another to evaluate Oncosec Medical Inc's financial trajectory
Compare this 10-K Annual Report to its predecessor by reading our highlights to see what text and tables were
removed , and by Oncosec Medical Inc.